Mazzeo F, Bernocchi D, Cavalli C, Manini G
Gastroenterology and Endoscopy Centre, Borgonovo Val Tidone Hospital, Piacenza, Italy.
J Int Med Res. 1988 May-Jun;16(3):237-43. doi: 10.1177/030006058801600312.
The therapeutic activity and tolerability of epomediol were studied in 28 patients with chronic hepatopathies. Treatment was continued, parenterally, for 10 days (400-600 mg once daily by intravenous infusion). Clinical parameters (headache, right hypochondrial pain, bitter taste in the mouth, asthenia and nausea) and hepatic function (transaminase, alkaline phosphatase and gamma-glutamyl transpeptidase) showed significant improvements. Clinical and systemic tolerabilities of epomediol were satisfactory.
对28例慢性肝病患者研究了埃波二醇的治疗活性和耐受性。采用肠胃外给药方式持续治疗10天（通过静脉输注，每日一次，剂量为400 - 600毫克）。临床参数（头痛、右季肋部疼痛、口苦、乏力和恶心）及肝功能（转氨酶、碱性磷酸酶和γ-谷氨酰转肽酶）均有显著改善。埃波二醇的临床和全身耐受性良好。
